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Abstract Phenylbutyrate (PBA) is a histone deacetylase in-
hibitor known for inducing differentiation, cell cycle arrest,
and apoptosis in various cancer cells. However, the effects
of PBA seem to be very cell-type-specific and sometimes
limited exclusively to a particular cell line. Here, we provided
novel information concerning cellular effects of PBA in LN-
229 and LN-18 glioblastoma cell lines which have not been
previously evaluated in context of PBA exposure. We found
that LN-18 cells were PBA-insensitive even at high concen-
trations of PBA. In contrary, in LN-229 cells, 5 and 15 mmol/
L PBA inhibited cell growth and proliferation mainly by caus-
ing prominent changes in cell morphology and promoting S-
and G2/M-dependent cell cycle arrest. Moreover, we observed
nearly a 3-fold increase in apoptosis of LN-229 cells treated
with 15 mmol/L PBA, in comparison to control. Furthermore,
PBAwas found to up-regulate the expression of p21 whereas
p53 expression level remained unchanged. We also showed
that PBA down-regulated the expression of the anti-apoptotic
genes Bcl-2/Bcl-XL, however without affecting the expression
of pro-apoptotic Bax and Bim. Taken together, our results
suggest that PBA might potentially be considered as an agent
slowing-down the progress of glioblastoma; however, further
analyses are still needed to comprehensively resolve the na-
ture of its activity in this type of cancer.
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Introduction
Despite the extensive efforts undertaken to treat glioblastoma,
this cancer is now considered to be the most frequent type of
glial tumors with poor prognosis of survival. Current ap-
proaches of treatment include radiotherapy and chemotherapy
as well as surgical interventions, any of which is effective
enough to treat this incurable malignancy. The probable rea-
son of the difficulties in developing effective therapy against
glioblastoma is connected with the fact that these cancer cells
are very anaplastic and heterogeneous and highly active in
migrating along fiber tract and blood vessels to invade the
brain [1].
Recently, it has become evident that cancer development is
basically regulated by both genetic as well as epigenetic alter-
ations. Genetic changes in malignant gliomas have been ex-
tensively investigated and include mutations in main tumor
suppressor genes such as p53 or PTEN [2, 3] and deletions
of some parts of the chromosomes (e.g., 6q26-27, 1p36.23,
17p13.3-12) [4]. Currently, a great deal of attention has also
been shifted toward epigenetic regulation of cancer genesis
and progression. Methylation of the CpG islands in the pro-
moter regions of genes and chromatin structure remodeling
have also been identified as an important processes involved
in tumor development [5]. Alterations of the chromatin archi-
tecture are regulated by histone acetylation/deacetylation
modifications [6]. Nucleosomes composed of histones show-
ing low levels of acetylation are the hallmark of transcription-
ally silent chromatin; reversely, relaxed chromatin structure is
composed of highly acetylated histones [7, 8]. Histone acety-
lation status is guarded by two crucial groups of counteracting
* Magdalena Kusaczuk
mkusaczuk@wp.pl
1 Department of Pharmaceutical Biochemistry, Medical University of
Białystok, Mickiewicza 2A, 15-222 Białystok, Poland
2 Department of Microbiology, Institute of Biology, University of
Białystok, Białystok, Poland
Tumor Biol. (2016) 37:931–942
DOI 10.1007/s13277-015-3781-8
enzymes: histone acetyltransferases (HATs) and histone
deacetylases (HDACs) [7, 8]. HATs transfer acetyl groups
from acetyl-coenzyme A onto the amino groups of lysine res-
idues of histones, resulting in transcriptional activation. In
contrary, HDACs catalyze the removal of these acetyl moie-
ties from histone proteins causing chromatin tightening and
transcriptional repression [7, 9].
Acetylation homeostasis can be modulated by the group of
compounds called the histone deacetylase inhibitors
(HDACIs). Yet, five classes of HDACIs have been distin-
guished according to their structural characteristics: (i) organic
hydroxamic acids, (ii) short-chain fatty acids, (iii)
benzamides, (iv) cyclic tetrapeptides, and (v) sulfonamide
anilides [6, 7, 10].
Phenylbutyric acid (PBA) is a short-chain fatty acid known
to possess broad spectrum of molecular functions. It has been
primarily developed as an ammonia scavenger in urea cycle
disorder treatment. However, multiple researches conducted
over years have demonstrated other biological activities of
PBA. In this regard, PBA has been shown to display the ac-
tivity of a chemical chaperone at high concentrations and to
possess the ability of inhibiting HDACs [7]. PBA is charac-
terized by good bioavailability in vivo of approximately
3 mmol/L; nevertheless, higher concentrations ranging be-
tween 1 and 5 mmol/L have also been stated [11–13]. Because
of the low cytotoxicity of PBA and the effective cerebrospinal
fluid penetration, an interesting area of investigation
concerning its utility in brain tumor research has been opened
[14].
Among various activities of PBA, it has been demonstrated
to be the reversible inhibitor of class I and II HDACs [10].
PBA mode of action in cancer cells has been attributed to
reduced proliferation [15], enhanced differentiation [1, 16],
increased apoptosis [1, 17, 18], and cell cycle arrest [14, 18].
However, the molecular pathways underlying these processes
still seem to be only partially discovered. Apoptosis evoked
by PBA treatment has been suggested to be linked to the
down-regulation of many anti-apoptotic genes such as Bcl-
XL, Bcl-2, or survivin, as well as disrupted signal transduction
pathways responsible for cell survival, including down-
regulation of the and Akt and nuclear factor-κB (NF-κB) sig-
naling [19–21]. Moreover, the expression of some pro-
apoptotic (e.g., Bid, caspase-3, caspase-7, and caspase-8) mol-
ecules has been significantly up-regulated after PBA supple-
mentation [22, 23]. It has also been widely demonstrated that
the pro-apoptotic and cell cycle inhibiting effects of butyrates
are likely to be mediated by restoration of the p53-dependent
signaling pathways [24–26]. Furthermore, it has been proven
that cell cycle arrest is frequently connected with the strong
induction of the P21 expression [15, 27]. Other cell cycle
regulatory proteins have also been found to be deregulated
after PBA treatment. The expressions of both cyclins and
cyclin-dependent kinase (Cdk) inhibitors such as Cdk2,
Cdk4, cyclin D1, or cyclin A have been shown to be modu-
lated by PBA [28–30]. Nevertheless, cellular responses and
gene expression patterns initiated after PBA treatment are not
universal and seem to be very cell-type-specific. Although a
great deal of research concerning PBA functioning in cancer
has already been undertaken, the mechanism of
phenylbutyrate action in glioblastoma cells has not been com-
prehensively solved yet.
To extend the range of knowledge about PBA influence on
glioblastoma cells, we made an effort to determine the cell-
type-specific effects of phenylbutyrate in LN-18 and LN-229
cell lines. PBAwas found to have HDAC inhibitory effect in
both cell lines; however, only LN-229 cells displayed growth
inhibitory effect after PBA treatment. Our data indicate that
LN-229 cells showed marked dose-dependent inhibition of
cell proliferation, visible changes in cell phenotype, and in-
creased apoptosis after incubation with high concentration of
PBA in growth medium. Moreover, we observed pronounced
alterations in the cell cycle distribution, with noticeable ten-
dency to arrest the cells in S and G2/M phases. These effects
were accompanied by enhanced expression of p21 transcript,
while the unchanged p53 expression status was observed,
suggesting p53-independent mode of action. Furthermore,
the expressions of the main anti-apoptotic genes Bcl-2/Bcl-
XL were significantly down-regulated. To our knowledge, this




Dulbecco’s modified Eagle’s medium (DMEM), containing
glucose at 4.5 mg/mL (25 mM) with Glutamax, penicillin,
streptomycin, trypsin-EDTA, and High Capacity RNA-to-
cDNA Kit were provided by Invitrogen (San Diego, USA);
passive lysis buffer, ReliaPrep RNA Cell Miniprep System,
and HDAC-Glo™ I/II Assay and Screening System by
Promega (Madison, USA); FBS Gold by Gibco (USA); fluo-
rescein isothiocyanate (FITC) Annexin VApoptosis Detection
Kit I by BD Pharmingen (CA, USA); and RNase by
AppliChem (Darmstadt, Germany). 4-Phenylbutyrate was
purchased from Enzo Life Sciences, Inc. (Lausen, Switzer-
land) and molecular-grade purity water from Sigma-Aldrich
(St. Louis, MO, USA),
Cell cultures
Human glioblastoma cell lines LN-229 and LN-18 were kind-
ly provided by Prof. Cezary Marcinkiewicz from the Depart-
ment of Neuroscience, Temple University, Philadelphia, USA.
Cells were maintained in high-glucose DMEM supplemented
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with 5 % heat-inactivated fetal bovine serum GOLD (FBS
GOLD), 2 mmol/LL-glutamine, penicillin (100 U/mL), and
streptomycin (100 μg/mL). Cells were cultured in Falcon
flasks (BD) in a 5 % CO2 incubator (Galaxy S+; New Bruns-
wick), at 37 °C. Subconfluent cultures were detached with
0.05 % trypsin 0.02 % EDTA in calcium-free phosphate-buff-
ered saline (PBS) and counted in cell counter Scepter
(Millipore).
Determination of HDAC inhibitor potency
HDAC activity was measured using luminescent HDAC-
Glo™ I/II Assay and Screening System (Promega) according
to the manufacturer’s protocol. Briefly, cells were seeded in
96-well white-walled culture plates at a density of 10,000
cells/well. Attached cells were incubated with various concen-
trations of PBA solution (0.5–15 mmol/L) for 1 h at 37 °C.
After incubation period, 100 μL of the HDAC-Glo™ I/II Re-
agent with Triton® X-100 in a final concentration of 1 % was
added to each well, and cells were incubated at room temper-
ature for another 35 min. Luminescence was measured on a
microplate reader (Tecan, Switzerland), at signal steady-state
35min after adding the HDAC-Glo™ I/II Reagent to the cells.
Experiment was performed in triplicates.
Cell viability
Cell viability was measured according to the method of
Carmichael et al. [31] using 3-(4,5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT). Briefly, cells were
seeded in 24-well plate at a density of 5×104 per well. Con-
fluent cells, cultured for 24 and 48 h with different concentra-
tions of PBA (0.5–15 mmol/L), were washed three times with
PBS and then incubated with 1 mL ofMTTsolution (0.25 mg/
mL in PBS) for 4 h at 37 °C in 5 % CO2 in an incubator. The
medium was removed, and 1 mL of 0.1 mmol/L HCl in abso-
lute isopropanol was added. Absorbance of converted dye in
living cells was measured at wavelength of 570 nm on a mi-
croplate reader (Tecan). The viability of LN-229 and LN-18
cells was calculated on the basis of optical density, as a per-
centage of the cell survival in PBA-treated wells in relation to
cell survival in the control wells. All the experiments were
done in triplicates in at least three cultures.
Cell morphological analysis
Acridine orange (AO)/ethidium bromide (EtB) double stain-
ing and fluorescent as well as phase contrast microscopy was
used to observe morphological changes in the glioblastoma
LN-229 cells. AO is taken up by both viable and dead cells.
Green fluorescence occurs when AO binds to double-stranded
DNA in living cells and red fluorescence, when it binds to
single-stranded DNA which dominates in dead cells. EtB is
excluded from living cells [32]. Of LN-229 cells, 2.5×105
were seeded into six-well plates and incubated with 5 or
15 mmol/L PBA for 24 and 48 h at 37 °C in a humidified,
5 % CO2 atmosphere. After incubation, the cells were stained
with mixture of AO (10 μmol/L) and EtB (10 μmol/L). The
cells were viewed under a fluorescent and phase contrast mi-
croscope (Olympus, CKX 41) at×100 or×200 magnification.
Detection of apoptosis
The cells (2.5×105 in 2 mL of medium) were seeded in six-
well plates and incubated until they achieved confluence. The
LN-229 cells were incubated in the high-glucose DMEMwith
5 or 15 mmol/L PBA. The incubation was continued for 24
and 48 h. The cells were trypsinized and resuspended in
DMEM and then in a binding buffer. Cells were stained with
FITC Annexin Vand PI for 15 min at room temperature in the
dark following the manufacturer’s instructions (FITC
Annexin V apoptosis detection Kit I). Flow cytometry was
performed using the FACSCanto II cytometer (Becton Dick-
inson). Data were analyzed with FACSDiva software, and
dead cells were excluded based on forward- and side-scatter
parameters. Percentage of apoptotic cells as a sum of Q2 and
Q4 quadrant and necrotic cells as a Q1 quadrant population of
analyzed cells was presented.
Cell cycle analysis
LN-229 cells were seeded into six-well plates at a density of
2.5×105 cells per well and incubated for 24 and 48 h with 5 or
15 mmol/L PBA. After this time, cells were detached and
fixed with 1 mL of 70 % ethanol and kept at −20 °C for at
least one night. Subsequently, the cells were washed, resus-
pended in PBS, and treated with 50 mg/mL of DNase-free
RNase A (AppliChem). Finally, cells were stained with
100 μg/mL of PI and fluorescence was read by a flow
cytometer FACSCanto II.
RNA isolation
Total cellular RNA was extracted using the ReliaPrep
RNA Cell Miniprep System (Promega) and treated with
DNase I according to the manufacturer’s protocol.
Quantity of the purified RNA was measured spectropho-
tometrically (A260/A280) using NanoPhotometer
(Implen, Germany). Quality of isolated RNA was
assessed by capillary electrophoretic measurement of
RNA integrity number (RIN) using Bioanalyzer 2100
(Agilent, Palo Alto, CA). Samples with RIN values ex-
ceeding 9 were taken for further analyses.
Tumor Biol. (2016) 37:931–942 933
Gene expression analysis
Reverse transcriptase (RT) reactions were performed using a
High Capacity RNA-to-cDNA Kit (Invitrogen) according to
the manufacturer’s protocol. Briefly, 1 μg of purified total
RNAwas used in a 20-μL reactionmixture containing dNTPs,
random octamers, and oligo dT-16 primers andMuLVRT. For
real-time qPCR reactions, 2 μL of cDNA served as a template
to subsequent product amplification using 2xHS-PCR Master
Mix SYBR A (A&A Biotechnology, Poland). The sequences
of the PCR primers were as previously described: p53: F-
GTTCCGAGAGCTGAATGAGG, R-TTATGGCGGGAG
GTAGACTG [33], p21: F- GGAAGACCATGTGGACCT
GT, R-GGCGTTTGGAGTGGTAGAAA [33],Bax: F-GA-
GAGGTCTTTTTCCGAGTGG, R-CCTTGAGCACCAGT
TTGCTG [34],Bim: F-CGTTAAACTCGTCTCCAATACG




CATTCACT [36], TRAIL: F-GCTCTGGGCCGCAAAAT,
R-TGCAAGTTGCTCAGGAATGAA [37] and for house-
keeping RPL13A: F-CTATGACCAATAGGAAGAGCAA
CC, R-GCAGAGTATATGACCAGGTGGAA [38]. Primers
were additionally checked for their accuracy by BLAST and
Primer-BLAST software. Reaction parameters were as fol-
lows: initial denaturation at 95 °C for 3 min, followed by
40 cycles of 95 °C for 1 min, 59 to 69 °C for 30 s, and
72 °C for 45 s. Real-time qPCR reactions were run in tripli-
cates in CFXConnect Real-Time PCR System (Bio-Rad), and
collected data were analyzed using relative quantification
method modified by Pfaffl [39].
Statistical analysis
All data are expressed as means±SD from three independent
experiments run in triplicates. Statistical analyses were per-
formed using Statistica Data Miner (StatSoft, Poland). The
differences in each parameter were evaluated by a one-way
analysis of variance (ANOVA) followed by the post hoc
Tukey test for pairwise comparison between different groups.
GraphPad Prism 5 software (GraphPad Software, Inc., USA)
was used to count the IC50 values. The significant differences
of means were determined at the level of *p<0.05 and
**p<0.001.
Results
The effect of phenylbutyrate on HDAC activity
To confirm HDAC inhibitory potential of PBA in glioblasto-
ma cells, the luminescent assay usingHDAC-Glo™ I/II Assay
and Screening System (Promega) was performed. The relative
activity of HDAC class I and II enzymes in cells subjected to
phenylbutyrate treatment was measured. Figure 1 shows that
PBA is very effective in inhibiting HDAC activity in both LN-
229 as well as LN-18 cells and that this inhibition is strictly
dose-dependent. Data were plotted against logarithmic values
of PBA concentrations (from 0.5 to 15 mmol/L), and IC50 for
HDAC inhibition was determined using GraphPad Prism 5
software. The estimated IC50 values for LN-229 and LN-18
cells were 1.21 and 1.92 mmol/L, respectively. These results
show that PBA is slightly more potent in inhibiting HDAC
activity in LN-229; however, this difference was not of statis-
tical significance.
The effect of phenylbutyrate on cell viability
The anti-proliferative effect of PBA was assessed by MTT
method in LN-229 and LN-18 glioblastoma cell lines cultured
with increasing concentrations of phenylbutyrate for periods
of 24 and 48 h. Figure 2a shows that PBA, in the concentra-
tions from 0.5 to 15 mmol/L, caused dose-dependent reduc-
tion of LN-229 cell viability but notwithstanding the time. An
evident inhibition of LN-229 cell viability was observed as
early as 24 h after PBA treatment. In cells treated with
15 mmol/L PBA, the effect on cell viability was markedly
more pronounced than in others; thereby, this concentration
of PBA was found to diminish cell viability by over 70 %
(Fig. 2a). The IC50 values of PBA were calculated using
GraphPad Prism 5. For LN-229 cells, the IC50 value was ap-
proximately 5.45 mmol/L, while LN-18 cells were clearly
PBA-insensitive. Interestingly, PBA treatment had almost no
cytotoxic effect in LN-18 cell line, where the highest dose of
PBA caused only 15 % reduction in cell viability (Fig. 2b). In
this respect, only LN-229 cells were chosen for further study
Fig. 1 HDAC inhibitor potency of PBA. Data were plotted against
logarithmic values of PBA concentrations (ranging from 0.5 to
15 mmol/L), and IC50 values of HDAC inhibition were determined
using GraphPad Prism 5 software. Data represent the mean±standard
deviations of three replicates
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and two representative concentrations of phenylbutyrate lower
(5 mmol/L) and higher (15 mmol/L) than IC50 value were
selected for further examinations.
The effect of phenylbutyrate on cell morphology
To check if the decrease in cell viability of LN-229 cells was
mirrored in changed cell morphology and enhanced apoptosis,
the microscopic observations were made. Figure 3a shows the
phenotypic characteristics of LN-229 cells seen under phase
contrast microscope. LN-229 cell density was visibly reduced
following 24 h of PBA treatment with 5 as well as 15 mmol/L
PBA; however, the most prominent proliferation-suppressive
effect was observed after 48-h incubation with 15 mmol/L
PBA. Moreover, the substantial changes in cell shape were
also noticed (Fig. 3a). To identify the apoptotic cells, the
AO/EtB staining was performed and cells were observed un-
der fluorescent microscope. This method distinguished viable
cells by appearing with green nuclei, while dead cells by
showing red nuclei. Figure 3b displays representative photo-
graphs of AO/EtB-stained LN-229 cells incubated for 24 and
48 h with 5 or 15 mmol/L phenylbutyrate, in comparison to
the non-treated controls. PBA treatment caused visible chang-
es in cell morphology and density; however, we observed only
slight proportion of cells with red-stained nuclei indicative of
late apoptosis, which suggested that apoptotic events might be
only marginally responsible for the reduction of cell density.
Variations in cell morphology were PBA concentration-de-
pendent. The most prominent effect was noticeable after
48 h of treatment with the highest concentration of
phenylbutyrate. These cells showed an enlarged, swollen cell
morphology and increased cytoplasm with visibly more con-
densed nuclei and an evident loss of spindle-shaped cells,
when compared with controls.
The effect of phenylbutyrate on apoptosis
To examine the mechanism of the cytostatic effect of PBA in
LN-229 cells, we investigated whether the activity of
phenylbutyrate is associated with apoptosis. To explicitly con-
firm the microscopic results of the AO/EB staining, LN-229
cells were exposed to PBA at the determined concentrations,
and apoptotic cells were evaluated by flow cytometry analy-
sis. The percent of apoptotic LN-229 cells in cultures incubat-
ed with 5 or 15 mmol/L of PBA for 24 and 48 h is reflected in
Fig. 4. We did not observe any effect of phenylbutyrate on the
apoptosis of LN-229 cells incubated with 5 mmol/L of PBA
notwithstanding the time of incubation. Only in the case of
cultures incubated with 15 mmol/L of phenylbutyrate, we ob-
served a significant nearly 3-fold increase in apoptosis in com-
parison to control cells. However, it is worth of note that the
cells detected as apoptotic were mostly at the early apoptotic
phase. It is interesting that PBA, at the concentration of
15 mmol/L, evoked apoptosis to a similar extent after 24 h
(22.13 %±0.26) as well as after 48 h (22.16±0.49) of incuba-
tion. It suggests that PBA is acting in strictly dose-dependent
but not time-dependent manner (Fig. 4).
The effect of phenylbutyrate on cell cycle distribution
To further evaluate if the proliferation-suppressive mechanism
of PBA on glioblastoma cancer cells was attributable to the
cell cycle arrest, we monitored the changes in the cell cycle
distribution by the flow cytometry method. We observed that
the cell cycle distribution of LN-229 cells was interrupted by
PBA treatment (Fig. 5). The results of 24- and 48-h treatment
indicated that glioblastoma cells subjected to 5 and 15mmol/L
concentrations of PBA showed different distributions of the
cell cycle phases (Fig. 5a). After 24 h of incubation with
5 mmol/L of PBA, we did not observe almost any changes
in the G1 phase cells; however, we noticed marked decrease in
Fig. 2 The viability of glioblastoma cancer cells treated with different
concentrations of phenylbutyrate for 24 and 48 h of LN-229 (a) and LN-
18 (b) cell line. The results represent means for pooled triplicate values
from three independent experiments. Significant changes are expressed
relative to controls and marked with asterisks. Statistical significance was
considered if *p<0.05
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S phase cells (16.3 vs. 5.4 %) and the significant increase in
G2/M phase cells (12.7 vs. 19.2 %) in comparison to the
control (Fig. 5b). In contrast, 48-h treatment with 5 mmol/L
of PBA resulted in complete decrease in G1 phase, with si-
multaneous dramatic increase in S (13.9 vs. 70.1 %) and G2/
M phase cells (14.3 vs. 28.5 %) (Fig. 5b). The effects of
5 mmol/L PBA treatment seemed to be augmented in higher
15 mmol/L PBA concentration. Accordingly, after 24 h,
15 mmol/L PBA caused instantaneous depletion in G1 phase
cells accompanied by the dramatic increase in S phase cells
(16.3 vs. 79.8 %) and significant increase in G2/M phase
(Fig. 5b), while 48-h treatment shifted practically all the cell
population (92.5 %) toward G2/M phase (Fig. 5b). These re-
sults indicate that LN-229 cells did not undergo an immediate
cell cycle arrest after 24 h of 5 mmol/L PBA treatment; how-
ever, 15 mmol/L of PBA accelerates the transition through the
G1/S phase and enables the S/G2 progression, resulting in
complete loss of cells in G1 phase. After 48 h, both
concentrations evoked total depletion of G1 phase cells with
a prominent increase in cells being at S- and G2/M phases.
Therefore, we conclude that PBA is able to induce the cell
cycle arrest in S and G2/M phases, and this effect is clearly
time- and dose-dependent.
The effect of phenylbutyrate on gene expression
HDACI mode of action is connected with altered transcrip-
tional regulation and changed pattern of gene expression. To
investigate if the apoptotic and cell cycle altering effects of
PBA were due to the changes in gene expression, we per-
formed RT-qPCR analyses of some genes involved in cell
cycle control and apoptosis. Phenylbutyrate is mostly known
for evoking cellular effects in P53/P21-dependent manner.
According to this, to check if the PBA-mediated cell cycle
disturbances in LN-229 cells involve this molecular pathway,
we measured the expression of p53 and p21 on the messenger
Fig. 3 The phenotypic
characteristic of LN-229 cells
after 24 and 48 h of PBA
treatment. Representative
photographs are shown.
Morphological effects induced by
5 and 15 mmol/L PBA after
24- and 48-h treatment, a
evaluated by phase contrast
microscopy (magnification×
100). Evident reduction of cell
density was observed, b evaluated
by the acridine orange/ethidium
bromide staining, shown by
fluorescence microscopy
(magnification×200). Markedly
enlarged cells with bright yellow,
condensed nuclei are visible
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RNA (mRNA) level. Interestingly, we did not observe any
changes in p53 transcript, but a significant increase in p21
expression was noticed. After 24 h of 5 mmol/L PBA treat-
ment, the expression level of p21 was not significantly al-
tered; however, incubation with 15 mmol/L of PBA resulted
in significant up-regulation of p21 (1.7-fold change in com-
parison to control). Forty-eight-hour treatment with both 5
and 15 mmol/L of PBA caused over 2-fold increase in the
expression level of p21 (Fig. 6). These results may suggest
that PBA treatment affects LN-229 cells without engaging
P53-mediated signaling. Next, we decided to identify the
probable pathways involved in PBA-mediated cell death.
Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) as the up-stream activator of death receptors was
chosen to indicate the potential involvement of extrinsic ap-
optotic pathway. However, we did not see any changes in its
expression. Finally, we decided to investigate if the media-
tors of the mitochondrial apoptotic pathway are engaged in
evoking LN-229 cell apoptosis. Accordingly, we analyzed
the level of Bim, Bax, Bcl-2, and Bcl-XL expression. We
did not observe significant changes in the expression of
pro-apoptotic Bim or Bax. It is interesting that we did notice
a significant down-regulation of the anti-apoptotic Bcl-2 and
Bcl-XL mRNAs. Surprisingly, the decrease of Bcl-2/Bcl-XL
transcript levels was pronounced independently on the PBA
concentration, while the flow cytometry analysis showed
enhanced apoptosis only in 15 mmol/L PBA. This observa-
tion suggests that deregulation of transcription of the genes
involved in mitochondrial-derived apoptosis might play an
important role in regulation of PBA-dependent apoptosis in
LN-229 cells. Nevertheless, the role of this mechanism can-
not be undoubtedly stated.
Discussion
Despite many researches exploring PBA influence on various
cancer cell lines have already been conducted, the molecular
mechanisms initiated during PBA-mediated cellular responses
are still incompletely understood. The effects of PBA seem to
be very cell-type-specific and sometimes limited exclusively
to a particular cell line. To uncover more information about
PBA activity in glioblastoma, we decided to investigate the
effect of PBA treatment on LN-18 and LN-229 glioblastoma
cell lines, which have not been evaluated in the context of
PBA responsiveness yet. In our study, we provided novel
information concerning cellular effects of phenylbutyrate
treatment in glioblastoma cells.
It has been well established that HDAC inhibitors affect
many aspects of cellular functioning. The primary effect of
HDACIs is attributed to the alterations in the gene expression
patterns caused by changes in chromatin structure. PBA has
been extensively examined in various cancer cell lines show-
ing good efficacy in triggering cell differentiation, G1 cell
cycle arrest, and apoptosis [7]. Nevertheless, modest number
of data exists in context of how PBA influences glioblastoma
cells. There have been reports that phenylbutyrate exhibits the
growth inhibitory effect in various glioblastoma cell lines
mostly through the induction of cell cycle arrest, apoptosis,
cell differentiation, and radiosensitization [14, 27]; however,
the results of clinical trials were not as satisfactory as cell line-
based studies [40].
In our study, we observed that although PBA inhibited the
activity of HDACs in both cell lines to a similar extent, only
LN-229 cells showed drastic dose-dependent reduction of cell
viability. LN-18 cells seemed to be PBA-resistant even at high
Fig. 4 The effect of phenylbutyrate on apoptosis of glioblastoma cells.
The cells were incubated with 5 and 15 mmol/L PBA for 24 and 48 h. a
Representative FACS data for LN-229 cells subjected to Annexin V-
FITC/propidium iodide staining. b Bar graph presenting the percentage
of apoptotic cells. Mean values from three independent experiments±SD
are shown. Significant alterations are expressed relative to controls and
marked with asterisks. Statistical significance was *p<0.05 or
**p<0.001
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concentrations of phenylbutyrate (exceeding 10 mmol/L of
PBA in culture medium). We noted marginal, about 15 %,
decrease in viability of the LN-18 cells, which, although sta-
tistically relevant, did not result in any significant cellular
effects in these cells (data not shown). This observation seems
to be confusing since it might suggest HDAC inhibitory-
independent mode of PBA action. Since PBA is class I and
II HDAC inhibitor, one of our hypotheses trying to explain
this phenomenon is connected with the cellular localization of
class II HDACs. These enzymes may localize in the nucleus
and cytoplasm, suggesting potential extranuclear functions
connected with regulation of the acetylation status of non-
histone proteins [41]. Acetylation of non-histone proteins
has been shown to alter protein functions by modifying their
stability, cellular localization, and protein–nucleotide/protein–
protein interactions. Well-known targets of non-histone acet-
ylation include essential cellular signaling mediators and tran-
scription factors such as the following: p53, NF-κB, p65,
Fig. 5 The effect of phenylbutyrate on cell cycle distribution of LN-229
glioblastoma cell line. The cell cycle was measured by propidium iodide
staining followed by flow cytometry analysis. Results are shown for cells
treated with 5 and 15 mmol/L PBA for 24 and 48 h versus untreated
controls. a Graphical representation of the cell cycle profiles obtained
from flow cytometry measurements. b Bar graph presenting the
percentage of cell cycle distribution in LN-229 cells. Significant
alterations are expressed relative to controls and marked with asterisks.
Statistical significance was *p<0.05 or **p<0.001
938 Tumor Biol. (2016) 37:931–942
(CREB)-binding protein (CBP), p300, STAT3, tubulin, PC4,
GATA factors, nuclear receptors, c-Myc, hypoxia-inducible
factor (HIF)-1α, FoxO1, heat-shock protein (Hsp)-90, cell
cycle regulator-E2F, FLT3 kinase, c-Raf kinase, and many
others [42]. It is noteworthy that many non-histone targets of
acetylation are factors relevant for tumorigenesis, cancer cell
proliferation, and immune functions. Perhaps, different pat-
tern of protein expression or the mutation status of genes being
potential targets of non-histone acetylation in LN-18 and LN-
229 cells might potentially be connected with differential re-
sponse to PBA treatment. Nevertheless, these assumptions
must be treated with caution, and further comprehensive anal-
yses on the transcriptomic and proteomic level are required to
undoubtedly solve this issue. Our results of cell sensitivity to
PBA seem to be supported by the observations of Lopez et al.
who examined four glioblastoma cell lines (D54, U-251, U87-
MG, and SKMG-3) and found U87-MG cells to be PBA-
insensitive even after 5 days of treatment [14]. The authors
have not figured out the mechanisms underlying this lack of
U87-MG sensitivity to PBA. They have suggested that this
might be related to the P53 status of the cells; however, this
assumption fails to explain our results, since both LN-18 and
LN-229 cell lines share mutated P53. This confirms highly
cell-type-dependent mode of action of phenylbutyrate. Ac-
cording to this, we decided to conduct further experiments
on LN-229 cell line only.
We noticed that the disturbances in cell viability were mir-
rored in diminished cell proliferation and altered cell morphol-
ogy. Microscopic observations confirmed that LN-229 cells
subjected to PBA treatment showed visible reduction in cell
density and changes in cell phenotype. We observed promi-
nent enlargement of cells with loss of spindle-shaped cells.
This is consistent with previous studies demonstrating pheno-
type modulatory effect of PBA on glioblastoma, medulloblas-
toma, or human liver carcinoma cells [1, 43, 44]. Interestingly,
obvious nuclear condensation was also visible, especially in
cells treated with high concentrations of PBA. Nuclear con-
densation might be an indicator of cells undergoing apoptosis.
Surprisingly, we did not manage to confirm any increase in
apoptotic cell death in cells treated with 5 mmol/L PBA. Only
15 mmol/L PBA-treated cells showed significant increase in
apoptosis ratio. The mechanisms responsible for PBA-
mediated apoptotic cell death are not clear. It has been report-
ed that in MCF7 breast cancer cells and DU145 prostate can-
cer cells, Fas/Fas ligand tract might be involved in apoptosis
induction [45, 46], while other reports showed down-
regulation of the anti-apoptotic Bcl-2/Bcl-XL and overexpres-
sion of the pro-apoptotic Bax, Puma, and Noxa proteins as the
potential mechanism of apoptosis initiated during PBA treat-
ment [21, 24]. These discrepancies in phenylbutyrate-
dependent modes of action between different cell lines suggest
that both extrinsic or mitochondrial pathways might be in-
volved in PBA-mediated apoptosis. TRAIL, as an upstream
activator of death receptors DR4 and DR5, might indicate the
involvement of extrinsic apoptotic pathway in cell death pro-
cess. Our results showed no significant changes in TRAIL
expression. This finding is in agreement with previous report
of Zhang et al. who demonstrated that neither Fas/Fas ligand,
tumor necrosis factor (TNF)-α, TNF-β, nor TRAIL expres-
sions were altered by PBA treatment [17]. However, we found
a prominent decrease in anti-apoptotic Bcl-2 and Bcl-XL tran-
scripts but no changes in pro-apoptotic Bax and Bim mRNA
levels, in cells treated with either 5 and 15 mmol/L PBA. Our
findings support the results of previous studies conducted on
prostate cancer cells demonstrating down-regulation of Bcl-2
and Bcl-XL [21, 46]. However, the up-regulation of pro-
apoptotic genes was not confirmed in our studies. Notably,
in previous works reporting higher expressions of pro-
apoptotic proteins such as Bax, analyses were performed on
protein level [24, 46]. We hypothesize that this increase in
expression of the apoptosis agonists might rather be the result
of protein-protein interactions, since anti-apoptotic Bcl-2 and
Fig. 6 Relative quantification of gene expression in RNA extracted after
24 and 48 h from LN-229 cells treated with 5 and 15 mmol/L of PBA.
Results are shown as a relative fold change in mRNA expression in
comparison to control, where expression was set as 1. Statistical
significance was considered if *p<0.05
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Bcl-XL may bind and inactivate pro-apoptotic Bim and Bax
[47]. In this respect, the down-regulation of anti-apoptotic
Bcl-2 and Bcl-XL genes resulting in lower expression levels
of their protein products might be sufficient to cause an in-
crease in protein level of unbound pro-apoptotic molecules.
Nevertheless, this mechanism does not profoundly explain the
pattern of apoptosis induction by PBA in LN-229 cells, since
marked down-regulation of Bcl-2/Bcl-XL and no influence on
Bim and Bax were observed with both (5 and 15 mmol/L)
concentrations of PBA, and significant apoptotic cell death
was found only in cells grown with 15 mmol/L of PBA. This
suggests that more complicated pathways are involved in me-
diating apoptotic process in phenylbutyrate-supplemented
cells, and considering only primary –gene expression modu-
latory effect of PBA might be insufficient to elucidate its role
in cellular processes. Thus, further complex analyses on tran-
scriptional as well as proteomic level should be done to com-
prehensively explain these mechanisms.
Nevertheless, apoptosis-evoking effect of PBA seems not
to be the main mechanism underlying the inhibition of LN-
229 cell proliferation. Since only 20 % of the cells were killed
after stimulation with 15 mmol/L of PBA, it seems reasonable
to have doubts if PBA treatment may be sufficient to give
effective glioblastoma-suppressive effect in monotherapy. In-
deed, PBA is a reversible HDAC inhibitor and normal level of
histone acetylation has been proven to be restored after drug
removal [14, 48, 49]. Nonetheless, it has been demonstrated
that PBA shows radiosensitizing and chemosensitizing effect
in glioblastoma cells [14, 50, 51]. In this respect, PBA might
rather be considered as a well-tolerated non-toxic co-
therapeutic cytostatic drug, continuously taken to support con-
ventionally accepted treatments.
We further found that PBA strongly influences cell cycle
distribution in LN-229 cells. Cell cycle analysis revealed that
PBA caused cell cycle arrest at the S and G2/M phases ac-
companied by a complete loss of cells in G1. These results
give a new insight into cell cycle modulatory effect of PBA, as
they differ significantly from the findings presented in other
cancer studies. Most of the reports infer that PBA causes
strong induction of G1-dependent cell cycle arrest with prom-
inent reduction of cells at the S stage [28]. Here, it was inter-
esting to find that PBA evoked simultaneous shift of almost all
cells to S and, finally, G2/M phases, in time- and dose-
dependent manner, in LN-229 cells. Consistent with our find-
ings, Li et al. demonstrated that SGC-7901 and MGC-803
gastric carcinoma cell lines might be arrested at the S or G2/
M phases dependently on the PBA dosage [18]. In contrary,
Lopez et al. observed no changes in cell cycle distribution in
any of the tested glioblastoma cell lines (D54 cells, U87-MG,
U251, and SKMG-3) [14]. As far as we know, no one has ever
demonstrated that PBA may provoke such drastic changes in
cell cycle distribution of glioblastoma cells or any other cancer
cell line.
It has been assumed that the cell cycle inhibition in S
and G2/M phase is mediated by the up-regulation of
P53 and induction of P21 [52]. However, we did not
manage to find elevated level of p53 mRNA, while p21
was up-regulated in PBA-treated cells. It has been
known that Cdk inhibitor P21 may be induced by both
P53-dependent and P53-independent mechanisms, and
induction of P21 is attributable to cell cycle arrest
[53]. According to our findings, PBA-mediated stimula-
tion of p21 expression might seem to be P53-indepen-
dent, which would be consistent with the fact that LN-
229 cells possess mutated P53. It is already known that
eukaryotic cell cycle is controlled by the coordinated
activity of protein kinase complexes, consisting of a
Cdk and cyclins. Progression through G1 is regulated
by the cyclin A–Cdk2 complex, entry into S phase by
cyclin E–Cdk2 complex, and the G2/M phase transition
is driven by cyclin B–Cdc2. It is also known that these
cyclin–Cdk complexes often bind to the endogenous in-
hibitor proteins P21 and P27, which inhibit their kinase
activities and prevent cell cycle progression [54]. P21,
as a Cdk inhibitor, may also directly inhibit Cdk2,
Cdk3, Cdk4, and Cdk6 activity [55]. This may indicate
that S and G2/M cell cycle arrest observed in our study
might be mediated by P21; however, additional experi-
ments are still needed to provide a conclusive answer.
In cu r ren t s tudy, we prov ided ev idence tha t
phenylbutyrate inhibits growth and proliferation of LN-
229 glioblastoma cells in time- and dose-dependent
fashion and that this inhibition occurs mostly by pro-
voking S and G2/M cell cycle arrest and apoptosis. We
found that PBA was able to up-regulate the expression
of p21 however, without influencing p53 expression,
and that this up-regulation may be correlated with S
and G2/M cell cycle arrest. Moreover, the anti-
apoptotic genes Bcl-2/Bcl-XL were markedly down-regu-
lated, probably facilitating apoptotic cell death in LN-
229 cells. We also found that LN-18 cells were PBA-
insensitive, although possessing the same profile of
main oncogenes and tumor suppressor genes as LN-
229 cell line (mutated P53, deleted P14ARF and P16,
and wild-type PTEN). This shows that PBA may act in
clearly cell-type-specific way, and that mechanisms ini-
tiated during PBA-dependent response are variable and
complex. These discrepancies in cellular effects evoked
by phenylbutyrate might be the reason of unsatisfactory
results of PBA treatment in patients and unsuccessful
attempts to introduce PBA as a therapy for malignant
gliomas in clinics. Therefore, it is worthwhile to con-
currently determine all possible molecular mechanisms
activated by phenylbutyrate treatment to use it success-
fully as a potential single therapeutic or a co-therapeutic
agent for glioblastoma multiforme therapy.
940 Tumor Biol. (2016) 37:931–942
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